5 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 10 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Active not recruiting 2, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Praxis Precision Medicines: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures 30mg PRAX-628 - Focal Onset Seizure, Primary Generalized Epilepsy | Phase 2 | Recruiting | Praxis Precision Medicines | 50 | 2025-01-10 | 2025-04-03 |
| Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1) 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo - Focal Seizure | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 255 | 2024-12-11 | 2026-08-10 |
| A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE) PRAX-562 - SCN2A Encephalopathy, SCN8A Encephalopathy | Phase 2 / Phase 3 | Active not recruiting | Praxis Precision Medicines | 77 | 2023-08-02 | 2026-01-29 |
| A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses - SCN2A-DEE, Epilepsy | Phase 1 / Phase 2 | Active not recruiting | Praxis Precision Medicines | 60 | 2023-04-13 | 2026-08-03 |
| A Clinical Trial of PRAX-114 in Participants With Essential Tremor 10 mg PRAX-114, 20 mg PRAX-114, and Placebo, 10 mg PRAX-114 or 20 mg PRAX-114 - Essential Tremor | Phase 2 | Withdrawn | Praxis Precision Medicines | 2022-04-05 | 2022-11-30 | |
| A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder 60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114 - Post-traumatic Stress Disorder, Post Traumatic Stress Disorder | Phase 2 | Terminated | Praxis Precision Medicines | 11 | 2022-01-25 | 2022-12-01 |
| A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor 100 mg PRAX-944, 60 mg PRAX-944, Placebo - Essential Tremor | Phase 2 | Completed | Praxis Precision Medicines | 133 | 2021-10-14 | 2024-03-13 |
| A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Major Depressive Disorder 10 mg PRAX-114, 20 mg PRAX-114, 40 mg PRAX-114 - Major Depressive Disorder | Phase 2 | Completed | Praxis Precision Medicines | 110 | 2021-06-24 | 2022-08-19 |
| A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder PRAX-114, Placebo - Major Depressive Disorder | Phase 2 / Phase 3 | Completed | Praxis Precision Medicines | 216 | 2021-03-30 | 2022-07-21 |
| A Clinical Trial of PRAX-944 in Participants With Essential Tremor Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo - Essential Tremor | Phase 2 | Completed | Praxis Precision Medicines | 24 | 2020-03-03 | 2024-03-01 |
Essential Tremor (3) · Movement Disorders (3) · Depression (2) · Depressive Disorder (2) · Depressive Disorder, Major (2) · Mood Disorders (2) · Seizures (2) · Central Nervous System Diseases (1) · Epilepsy (1) · Epilepsy, Idiopathic Generalized (1) · Mental Disorders (1) · Stress Disorders, Post-Traumatic (1) · Stress Disorders, Traumatic (1) · Trauma and Stressor Related Disorders (1) · Tremor (1)
United States (10) · Australia (4) · Spain (3) · Brazil (2) · Canada (2) · Israel (1) · Italy (1) · Mexico (1) · New Zealand (1) · Poland (1) · United Kingdom (1)